Another week, another round of developments across psychedelic medicine. Below is our recap of what mattered to investors for the week of February 9–15, 2026.
Clearmind Medicine Inc. (CMND): Clearmind reports additional positive safety data for CMND-100 in alcohol use disorder
Clearmind Medicine announced additional topline safety results from the second cohort of its Phase I/IIa trial of CMND-100, a non-hallucinogenic oral candidate for alcohol use disorder, reporting no serious adverse events and good tolerability after six additional patients completed treatment. The multinational study is run with partners including Yale and Johns Hopkins. The favorable safety profile positioned the program to advance to its next stage.
Source: globenewswire.com
Psyence Biomedical Ltd. (PBM): Psyence secures long-term psilocybin and ibogaine supply via PsyLabs put-option deal
Psyence Biomedical entered a put-option agreement with supplier PsyLabs to lock in long-term access to GMP pharmaceutical-grade psilocybin and ibogaine while conserving near-term cash. The arrangement underpins Psyence's ongoing Phase IIb trial of nature-derived psilocybin (NPX-5) for adjustment disorder in palliative cancer care. Securing a dependable controlled-substance supply chain is a key operational hurdle for clinical-stage psychedelic developers.
Source: psyencebiomed.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.